<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/06700179-3003-48DD-8CDD-E7CA6698E4C5"><gtr:id>06700179-3003-48DD-8CDD-E7CA6698E4C5</gtr:id><gtr:firstName>Ray</gtr:firstName><gtr:surname>Norbury</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DDD240F0-BF92-43B0-A7BA-57217BB59E46"><gtr:id>DDD240F0-BF92-43B0-A7BA-57217BB59E46</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:surname>Sharp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1002025"><gtr:id>5404C2EB-483A-40D5-87DB-FFCDF50CFDE1</gtr:id><gtr:title>Modelling human habenula-5-HT2C interactions with high field-strength (7T), high-resolution pharmacological FMRI</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1002025</gtr:grantReference><gtr:abstractText>Depression is a serious and debilitating disease that can affect as many as 1 in 4 people at some point in their life. Despite the devastating impact of depression on individuals and society, we know very little about what happens in the brain when a person becomes clinically depressed, or how antidepressant medications work. 

We do know that serotonin, one of the brain?s chemical messengers, is important in controlling our mood (how happy or sad we are) and most of the drugs used to treat depression act on serotonin. What we do not know is why it can take many weeks for a person to feel better once they start taking an antidepressant, or why some people respond very well to treatment while others respond poorly or not at all. 

The principal aim of the current research proposal is to better understand what antidepressants do in the brain and how we can make them more effective. We have shown that a very small and largely ignored part of the brain called the habenula is very important in controlling the levels of serotonin in the brain, especially when people first start to take antidepressants. Part of our research will look at this control pathway using Functional Magnetic Resonance Imaging (a technique that allows us to ?see? where the brain is active) to investigate if drugs that act in a particular way on the serotonin system also change the way this pathway functions. If we can ?switch off? this control pathway we may be able to make antidepressant drugs that work more quickly. 

The habenula is also involved in motivation and reward, and some depressed patients lack drive and often show reduced or blunted responses to rewarding events (psychiatrists call this anhedonia). These anhedonic patients are also sometimes the most difficult to treat. Dopamine, another of the brain?s chemical messengers, is very important for reward processing and we think that the habenula may control the release of dopamine through interactions with serotonin. Another part of our research will look at these dopamine/serotonin interactions with Functional Magnetic Resonance Imaging. If we can understand how the habenula interacts with dopamine, we may be able to better help those depressed patients who have very high levels of anhedonia.</gtr:abstractText><gtr:technicalSummary>Major depressive disorder (MDD) is the most common single psychiatric disorder worldwide and is associated with a high level of functional disability and impaired quality of life. Current first-line pharmacotherapies for MDD (e.g selective serotonin reuptake inhibitors [SSRIs]), while superior to placebo, frequently fail to render patients symptom free and there is a troublesome delay between starting medication and reported improvement in mood. There is a critical need therefore to identify novel antidepressant targets and develop improved treatment strategies. One possible therapeutic target that has attracted a great deal of interest recently is the habenula complex (Hb), a small structure located at the posterior-dorsal-medial end of the thalamus. Habenula efferents project to the dopaminergic ventral tegmental area (VTA) and the 5-HTergic dorsal raphe nucleus (DRN) where they act to inhibit cell firing. The Hb, therefore, is uniquely positioned both anatomically and functionally to play an important role in the regulation of both 5-HT and dopamine and, consequently, in the aetiology and pathophysiology of MDD and the therapeutic effects of antidepressants. The pharmacology of these control pathways is not yet fully understood, however recent preclinical work indicates a key regulatory role for the 5-HT2C receptor. The aim of the current proposal, therefore, is to use high-field (7T) high-resolution (voxel size 1mm3) Functional Magnetic Resonance Imaging (FMRI) in combination with the selective 5-HT2C agonist m-chlorophenylpiperazine (mCPP) to model Hb-DRN and Hb-VTA connectivity. We will use a randomised, placebo-controlled, within-subjects design. Participants (20 right-handed healthy volunteers) will attend two sessions separated by at least one week. At the first visit participants will receive either intravenous mCPP (0.08mg/kg) or saline placebo and the other infusion at the second visit. At each session participants will undergo a resting pharmacological challenge scan (phFMRI). We predict that: 1) Following mCPP challenge, Hb blood oxygenation level-dependent (BOLD) response will inversely correlate with that of the midbrain raphe region; and 2) Following mCPP challenge, Hb BOLD response will inversely correlate with that of the midbrain DRN and VTA. It is anticipated that our results will greatly increase our current understanding of the role of the Hb in 5-HT and dopamine homeostasis and may lead to advances in antidepressant treatment strategies.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>118177</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Partnership with Pharmacology</gtr:description><gtr:id>87B1F0B8-A11D-426F-96C1-1E92F3D21E1B</gtr:id><gtr:impact>This project is ongoing (completion date February 2013). This collaboration is multi-disciplinary including Psyciatry, Pharmacology and Psychology.</gtr:impact><gtr:outcomeId>cUCVpkqh2Ue-1</gtr:outcomeId><gtr:partnerContribution>Our partners have pioneered the development of animal models of antidepressant action and laid down some of the key anatomical pathways implicated in antidepressant response. Data that are invaluable if we are to develop new improved treatments for depression</gtr:partnerContribution><gtr:piContribution>We have contributed our imaging expertise which has facilitated the translation of animal models of antidepressant action to work in humans</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Schools</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0CD78F4F-40FD-4C69-AC47-4C3F1D537CB3</gtr:id><gtr:impact>We are committed to public engagement of science. As an example we have hosted, on two occasions, 6th form pupils from local schools. The pupils attended the University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR) and were were given a demonstration of the scanner in action, a 30-45 imin general presention on MagneticResonance Imaging (MRI) and an MRI data analysisdemonstraion. The pupils were also asked to work in small groups and develop their own FMRI experiment 'Which areas of the brain process colour'? The aim being to encourage the pupils to think about experimental design in general and also to think about what you can and cannot do with an MR scanner.

We have also hosted, on two seperate occasions, undergraduate psychology students from Oxford Brookes University.

Feedback provided by the teachers, lectures and pupils has been very positive. It is anticipated that similar presentations/workshops will continue and remain popular.</gtr:impact><gtr:outcomeId>S9jiiuhSXzi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Imaging the human habenula is challenging. The relatively small size of these nuclei mean that commonly used FMRI protocols have insufficient resolution and signal-to-noise ratio. Here, in our ongong project, we have combined very high-resolution FMRI with a simple reward task to first functionally localise the human habenula. In a novel step we then use these data to image habenula-dorsal raphe (Hb-DRN) and habenula- ventral tegmental area (Hb-VTA) feedback pathways with and without pharmacological manipulation.

Several pharmaceutical companies have interest in, or have a program of research into, 5-HT2C receptors as potential new treatments for depression and schizophrenia. Our human model of Hb-DRN and Hb-VTA feedback would, therefore, be extremely useful in the screening and characterisation of novel investigational products prior to randomised controlled trials for these disorders.</gtr:description><gtr:id>E94A23BD-F95B-4D37-A178-07ABCDBF8B7F</gtr:id><gtr:impact>Our human model of Hb-DRN and Hb-VTA feedback will likely be extremely useful in the screening and characterisation of novel investigational products prior to randomised controlled trials.</gtr:impact><gtr:outcomeId>AxHsygErWXa</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Habenula</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>11C9732F-319F-43F4-B524-BA54A4720AFF</gtr:id><gtr:title>Normal glutamate but elevated myo-inositol in anterior cingulate cortex in recovered depressed patients.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>pm_14432_12_19324421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>495D85AF-791D-4B6D-86B0-BDE0DFE720A2</gtr:id><gtr:title>Decreased regional gray matter volume in S' allele carriers of the 5-HTTLPR triallelic polymorphism.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f36a0b46d325daf7d58d5c21cdcf6fda"><gtr:id>f36a0b46d325daf7d58d5c21cdcf6fda</gtr:id><gtr:otherNames>Selvaraj S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_14432_22_21042318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FB4E71A-C3D8-4C52-9940-88D367E4A5AD</gtr:id><gtr:title>Increased neural response to fear in patients recovered from depression: a 3T functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_14432_12_19627640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>935DCE4C-B08E-43EB-991E-0885F03EFA89</gtr:id><gtr:title>Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d88219fbc18330d20e7155a934dbb5"><gtr:id>08d88219fbc18330d20e7155a934dbb5</gtr:id><gtr:otherNames>Godlewska BR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_14432_22_22716999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A02FA2D-49B9-4474-9ECB-4D38C9FF35D0</gtr:id><gtr:title>Risk for depression and neural responses to fearful facial expressions of emotion.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63b6351e8828949df7a286f7eaee0a86"><gtr:id>63b6351e8828949df7a286f7eaee0a86</gtr:id><gtr:otherNames>Chan SW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_14432_12_19182175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>807F7470-0D12-4A8C-9698-7A51809D4948</gtr:id><gtr:title>Neural response to angry and disgusted facial expressions in bulimia nervosa.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27920d4605b9dde1c99f4539f6cc0ac2"><gtr:id>27920d4605b9dde1c99f4539f6cc0ac2</gtr:id><gtr:otherNames>Ashworth F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_14432_22_21557893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03F53EB7-DAB4-4651-8428-B1B8105121CF</gtr:id><gtr:title>The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_14432_22_22488255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4D5AAB6-C140-4ACB-B64D-E59B3C4E5206</gtr:id><gtr:title>Short-term antidepressant treatment modulates amygdala response to happy faces.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_14432_12_19585106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA4C34CA-D315-43E3-B3A2-DBF7DA383541</gtr:id><gtr:title>Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>pm_14432_22_22449253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A6FD1DD-F1AE-4C56-9E51-968D4DBA313D</gtr:id><gtr:title>Elevated cortical glutamate in young people at increased familial risk of depression.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>pm_14432_22_20846462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2C05505-A568-42AE-A1DA-A05FAF939B7F</gtr:id><gtr:title>Lack of effect of citalopram on magnetic resonance spectroscopy measures of glutamate and glutamine in frontal cortex of healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/880cf52474bd701e7fe0e2f26464865f"><gtr:id>880cf52474bd701e7fe0e2f26464865f</gtr:id><gtr:otherNames>Taylor MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_14432_12_19423614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB98DF06-D607-48A8-8567-A6C694C12C1F</gtr:id><gtr:title>Neural correlates of the processing of self-referent emotional information in bulimia nervosa.</gtr:title><gtr:parentPublicationTitle>Neuropsychologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3932</gtr:issn><gtr:outcomeId>pm_14432_22_21843538</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31B3AB18-564D-4F24-BD49-373305F9C04C</gtr:id><gtr:title>Imaging vulnerability for depression.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_14432_22_21483436</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>057A36BD-2DF7-4F16-8A8C-396E81B5B7D8</gtr:id><gtr:title>A functional magnetic resonance imaging study of verbal working memory in young people at increased familial risk of depression.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_14432_12_19932468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C54AF39-29D2-49B2-97E7-DDD3E1E16E5C</gtr:id><gtr:title>Frontolimbic responses to emotional faces in young people at familial risk of depression.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883e93881f45f4205fb363e9972ff32e"><gtr:id>883e93881f45f4205fb363e9972ff32e</gtr:id><gtr:otherNames>Mannie ZN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>pm_14432_22_20952073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F98B8FA3-237E-455A-8C46-5E0C34AAC5A5</gtr:id><gtr:title>Short-term antidepressant administration reduces negative self-referential processing in the medial prefrontal cortex in subjects at risk for depression.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e9182640a623f56707624b00a3d534b"><gtr:id>3e9182640a623f56707624b00a3d534b</gtr:id><gtr:otherNames>Di Simplicio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>pm_14432_22_21358707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC510D63-C365-4751-B814-E6E81408A2A5</gtr:id><gtr:title>Effect of a single dose of citalopram on amygdala response to emotional faces.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn><gtr:outcomeId>pm_14432_12_19478294</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1002025</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>